Integer has completed its $5.7 billion sale to an affiliate of investment funds managed by KKR.
“Today marks an exciting new chapter for Integer, our associates, customers, and the patients we collectively serve,” Integer President and CEO Payman Khales said in the announcement. “Integer has built a reputation as a trusted partner to the world’s leading medical device companies and emerging innovators through our relentless focus on quality, customer service, and innovation.”
Integer serves the cardiovascular, neuromodulation, and cardiac rhythm management markets as one of the world’s largest medical device CDMOs. Integer is the 56th-largest medical device company in the world, according to the 2026 Medical Design & Outsourcing Medtech Big 100.

Integer President and CEO Payman Khales [Photo courtesy of Integer]
Related: What private equity means for medtech OEMs, suppliers and their employees
“We are pleased to officially welcome Integer to the KKR portfolio and look forward to building on the Company’s strong foundation alongside Payman and the management team,” KKR partner Max Lin said. “We see significant opportunities to leverage our resources and expertise to support Integer’s next phase of growth, expand its capabilities and strengthen its position as a trusted partner to the global medical device industry.”
The Texas-based CDMO announced the deal in August 2026 and shareholders approved it in October 2026. With the completion of the sale, Integer’s common stock ceased trading and will no longer be listed on the New York Stock Exchange. The company’s shareholders will receive $127 per share.
Integer is just the latest medical device contract manufacturer acquired by private equity firms this year, as the firms seek profit in the medical device market with CDMOs and larger OEMs.
Medtech pay analysis: Medtech CDMO Integer discloses executive pay after new CEO steps in



